SEPTEMBER 18, 2024 NEWS
Ascle Healthcare Group is pleased to announce the signing of a Memorandum of Understanding (MoU) with MIRXES Pte. Ltd. for the distributorship of GASTROClear services on 1st September 2022
GASTROClear is a cancer blood test designed to detect gastric cancer in people who may not yet be experiencing any symptoms. PHOTO: Ascle Healthcare Group
PUBLISHED IN SEP 2022
MIRXES Pte. Ltd. is a Singapore-headquartered biotechnology company focused on improving and saving lives with RNA-powered disease early detection tests. GASTROClear is a cancer blood test designed to detect gastric cancer in people who may not yet be experiencing any symptoms.
Together with MIRXES, we aim to change lives by providing preventive healthcare solutions to all people.
To find out more, please WhatsApp or Contact Us.
